STEGLATRO
Drug
PFIZER INC.
Total Payments
$22.8M
Transactions
40,000
Doctors
17,539
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $596,388 | 34 | 9 |
| 2023 | $478,454 | 14,171 | 8,457 |
| 2022 | $949,983 | 3,663 | 2,195 |
| 2021 | $794,334 | 1,987 | 1,489 |
| 2020 | $3.5M | 1,629 | 620 |
| 2019 | $6.0M | 8,541 | 4,115 |
| 2018 | $5.7M | 8,589 | 4,497 |
| 2017 | $4.8M | 1,386 | 27 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16.4M | 4,159 | 71.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.1M | 1,887 | 17.9% |
| Food and Beverage | $890,194 | 31,301 | 3.9% |
| Consulting Fee | $842,329 | 434 | 3.7% |
| Travel and Lodging | $587,203 | 2,197 | 2.6% |
| Space rental or facility fees (teaching hospital only) | $7,500 | 1 | 0.0% |
| Education | $315.66 | 21 | 0.0% |
Payments by Type
Research
$16.4M
4,159 transactions
General
$6.4M
35,841 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO | PFIZER INC. | $7.9M | 0 |
| RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN MK 8835PF 04971729 IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE THE VERTIS CV STUDY VERTIS EVALUATION OF ERTUGLIFLOZIN EFFICACY AND SAFETY | PFIZER INC. | $4.3M | 0 |
| SGLT2 INHIBITORS, KETONES, & CARDIOVASCULAR BENEFIT - PROTOCOL I | Merck Sharp & Dohme Corporation | $675,764 | 0 |
| A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin MK-8835,PF-04971729 in Pediatric Participants ages 10 to 17 years, inclusive with Type 2 Diabetes Mellitus | Merck Sharp & Dohme Corporation | $511,641 | 0 |
| A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin MK-8835,PF-04971729 in Pediatric Participants ages 10 to 17 years, inclusive with Type 2 Diabetes Mellitus | Merck Sharp & Dohme LLC | $459,193 | 0 |
| ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330,090 | 14 |
| The EMMED-HF Study Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure | Merck Sharp & Dohme Corporation | $293,636 | 0 |
| Ertugliflozin in acute heart failure Cardio-renal and diuretic effects | Merck Sharp & Dohme Corporation | $249,914 | 0 |
| Ertugliflozin in acute heart failure# Cardio-renal and diuretic effects | Merck Sharp & Dohme LLC | $240,509 | 0 |
| SGLT2 INHIBITORS, KETONES, & CARDIOVASCULAR BENEFIT - PROTOCOL I | Merck Sharp & Dohme LLC | $193,075 | 0 |
| Ertugliflozin in acute heart failure: Cardio-renal and diuretic effects | Merck Sharp & Dohme LLC | $189,190 | 0 |
| A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin MK-8835,PF-04971729 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin | Merck Sharp & Dohme Corporation | $164,824 | 0 |
| Ertugliflozin Cardioprotective Effects on Epicardial Fat | Merck Sharp & Dohme LLC | $143,759 | 0 |
| A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin MK-8835,PF-04971729 with Sitagliptin Compared with Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects with T2DM With Inadequate Glycemic Control on Metformin Monotherapy | Merck Sharp & Dohme Corporation | $137,035 | 0 |
| Effects of SGLT2 inhibition on cardiac mitochondrial function, energetics and remodeling in non-diabetic mice with heart failure with reduced ejection fraction | Merck Sharp & Dohme LLC | $98,893 | 0 |
| STUDY NAMEEffects of SGLT2 inhibition on cardiac mitochondrial function, energetics and remodeling in non-diabetic mice with heart failure with reduced ejection fraction | Merck Sharp & Dohme Corporation | $98,893 | 0 |
| Ertugliflozin Cardioprotective Effects on Epicardial Fat | Merck Sharp & Dohme Corporation | $80,485 | 0 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY | PFIZER INC. | $71,943 | 0 |
| The EMMED-HF Study# Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure | Merck Sharp & Dohme LLC | $66,473 | 0 |
| A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ertugliflozin MK-8835,PF-729 in Subjects with Type 2 Diabetes Mellitus with Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antidiabetic Therapy | Merck Sharp & Dohme Corporation | $34,966 | 0 |
Top Doctors Receiving Payments for STEGLATRO — Page 702
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Family Medicine | El Reno, OK | $3.12 | 1 |
| Michael Anderson | — | Yukon, OK | $3.12 | 1 |
| , DO | Family Medicine | Yukon, OK | $3.12 | 1 |
| , MD | Internal Medicine | Rockville, MD | $2.93 | 1 |
| , M.D | Internal Medicine | Omaha, NE | $2.71 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Cleveland, OH | $2.71 | 1 |
| , M.D | Internal Medicine | Omaha, NE | $2.71 | 1 |
| , M.D | Family Medicine | Dumont, NJ | $2.30 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $2.09 | 1 |
| , MD | Family Medicine | Des Moines, IA | $1.93 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Naples, FL | $1.60 | 1 |
| Ashley Legrand Rozovics | Student in an Organized Health Care Education/Training Program | Omaha, NE | $1.54 | 1 |
| Bruce Hillard | — | Toledo, OH | $1.54 | 1 |
| , DO | Family Medicine | Medina, OH | $1.46 | 1 |
| , M.D | Family Medicine | Elizabeth, PA | $1.33 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $13.2M
- Merck Sharp & Dohme Corporation $7.9M
- Merck Sharp & Dohme LLC $1.8M
Product Information
- Type Drug
- Total Payments $22.8M
- Total Doctors 17,539
- Transactions 40,000
About STEGLATRO
STEGLATRO is a drug associated with $22.8M in payments to 17,539 healthcare providers, recorded across 40,000 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2024. In 2024, $596,388 was paid across 34 transactions to 9 doctors.
The most common payment nature for STEGLATRO is "Unspecified" ($16.4M, 71.9% of total).
STEGLATRO is associated with 20 research studies, including "A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO" ($7.9M).